While there are currently no curative treatments available for WS, drug-repurposing efforts have identified several promising candidates, including ER stress modulators (e.g., valproate (VPA), originally a first-choice anti-epileptic drug), chemical chaperones (e.g., sigma-1 receptor (S1R) agonists), and antidiabetics (e.g., glucagon-like peptide 1 receptor (GLP-1R) agonists). The gene discussed is TMBIM4; the disease is Werner syndrome.